Klin Farmakol Farm. 2013;27(3-4):119-121
Current role of fibrates in treating dyslipidemia in patients with cardiometabolic syndrome
- Centrum preventivní kardiologie, 3. interní klinika 1. LF UK a VFN, Praha
Fibrates have been used in the treatment of dyslipidemia for a long time and, as a result, a number of data on their action are available
from various types of clinical trials. In addition to a comprehensive effect on the lipid profile, their use is accompanied by changes in other
parameters relevant to atherogenesis (parameters of inflammation, insulin sensitivity, or endothelial function). As has been shown in
randomized clinical trials performed in type 2 diabetics, fibrate treatment selectively reduces cardiovascular risk in patients with elevated
triglycerides and lower HDL-cholesterol level. Currently, fibrates are mainly used in combination therapy with statin that allows for
a safe reduction in residual vascular risk, particularly in persons with insulin resistance and metabolic syndrome. Treatment tolerance
is good and serious adverse effects occur rarely, similarly to the treatment with statins.
Keywords: fibrate, cardiovascular risk, insulin sensitivity, adverse effects
Published: December 1, 2013 Show citation
References
- WHO Cooperative trial committee of principal investigators. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators. Br Heart J1978; 40: 1069-1118.
Go to PubMed... - Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998; 98: 2088-2093.
Go to original source... Go to PubMed... - Češka R a kol. Cholesterol a ateroskleróza - léčba dyslipidémií. Triton, Praha 2012: 408.
- The FIELD study investigators. Effectsof long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366: 1849-1861. Go to original source... Go to PubMed...
- Grundy SM, Vega GL, Yuan Z, et al. Effectiveness and Tolerability of Simvastatin Plus Fenofibrate for Combined Hyperlipidemia (The SAFARI Trial) Am J Cardiol 2005; 95: 462-468. Go to original source... Go to PubMed...
- Nordestgaard BG, Freiberg JJ. Clinical relevance of non-fasting and postprandial hypertriglyceridemia and remnant cholesterol. CurrVascPharmacol. 2011; 9: 281-286. Go to original source...
- Chan DC, Pang J, Romic G, Watts GF. Postprandial hypertriglyceridemia and cardiovascular disease: current and future therapies. CurrAtherosclerRep 2013; 15: 300-309. Go to original source... Go to PubMed...
- Tenenbaum A, Fishman EZ. Fibrates are anessential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction. Cardiovascular Diabetology 2012; 11: 125-135. Go to original source... Go to PubMed...
- Rajamani K, Colman PG, Li LP, et al. FIELD study investigators. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet 2009; 373(9677): 1780-1788. Go to original source... Go to PubMed...
- Wright AD, Dodson PM. Medical management of diabetic retinopathy: fenofibrate and ACCORD Eyestudies. Eye (Lond) 2011; 25(7): 843-849. Go to original source... Go to PubMed...
- Sacks FM, Carey VJ, Fruchart JC. Combination lipid therapy in type 2 diabetes. N Engl J Med 2010; 363(7): 692-694. Go to original source...
- Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: review and meta-analysis. Lancet 2010; 375: 1875-1884. Go to original source... Go to PubMed...
- Jun M, Zhu B, Tonelli M, et al. Effects of fibrates in kidney disease. J AmCollCardiol 2012; 60: 2061-2071. Go to original source... Go to PubMed...
- Fruchart JC, Sacks FM, Hermans MP, et al. The residual risk initiative: a call to action to reduce residual vascular risk in dyslipideamic patients. Diabetes Vasc Dis Res 2008; 5: 319-335. Go to original source... Go to PubMed...